Login to Your Account

Oncolys Nabs $286M BMS Deal for Next-Gen NRTI Festinavir

By Tom Wall

Tuesday, December 21, 2010
Bristol-Myers Squibb Co. acquired exclusive, worldwide rights to manufacture, develop and commercialize festinavir, a once-a-day, orally available nucleoside reverse transcriptase inhibitor (NRTI) for HIV, from Oncolys BioPharma Inc., of Tokyo, a privately held company.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription